Curated News
By: NewsRamp Editorial Staff
September 17, 2026
Lantern Pharma's OMAI to Unveil AI Platform for Drug Development
TLDR
- Lantern Pharma's OMAI webinar offers investors a first look at its AI platform for accelerating drug development.
- OMAI uses multi-agentic AI to streamline therapeutic development from target discovery through clinical trials.
- Open-Medicine AI aims to expand precision oncology beyond rare cancers, potentially benefiting more patients worldwide.
- The Sept. 23 webinar will detail OMAI's architecture and its subscription-based business model for enterprise licensing.
Impact - Why it Matters
This news matters because it highlights the growing role of artificial intelligence in drug development, particularly in oncology. Lantern Pharma's OMAI platform represents a shift toward multi-agentic AI that could streamline therapeutic development from target discovery to clinical trials, potentially reducing the time and cost of bringing new treatments to patients. For investors, the webinar offers a deeper look into Lantern's business model and expansion plans, which could signal future revenue streams through subscription and licensing. As AI continues to disrupt biopharma, Lantern's progress with RADR and OMAI may position it as a key player in precision medicine, impacting how drugs are developed and delivered to patients. The event also underscores the importance of genomic data and machine learning in identifying the right patients for therapies, ultimately improving outcomes and efficiency in clinical trials.
Summary
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company that leverages artificial intelligence and genomic data to develop precision oncology therapies, will host a live webinar on Sept. 23 at 12:30 p.m. Eastern. The event will feature Panna Sharma, founder and CEO of Open-Medicine AI, Lantern's wholly owned subsidiary, presenting the business model, development roadmap, and value proposition of its multi-agentic AI platform for end-to-end therapeutic development. The webinar will cover OMAI platform architecture, expansion beyond rare cancers into additional disease categories and therapeutic modalities, and its planned subscription and enterprise licensing business model.
Lantern Pharma's proprietary RADR AI and machine-learning platform integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies and guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its CNS-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The webinar aims to showcase how OMAI's multi-agentic AI can transform therapeutic development, potentially reducing costs and accelerating timelines. Investors and industry watchers can find the full press release at https://ibn.fm/U9lmN and stay updated via the company's newsroom at https://ibn.fm/LTRN.
The announcement is disseminated through BioMedWire, a specialized communications platform for the biotech, biomedical, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and tailored corporate communications solutions. This infrastructure ensures that news like Lantern's webinar reaches a wide audience of investors, journalists, and the public, cutting through market noise to deliver actionable information.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma's OMAI to Unveil AI Platform for Drug Development
